Classifications

• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
  • A23L29/03—Organic compounds
  • A23L29/035—Organic compounds containing oxygen as heteroatom
  • A23L29/04—Fatty acids or derivatives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1629—Organic macromolecular compounds
  • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
  • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
  • A23L33/12—Fatty acids or derivatives thereof
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
  • A23P10/00—Shaping or working of foodstuffs characterised by the products
  • A23P10/20—Agglomerating; Granulating; Tabletting
  • A23P10/22—Agglomeration or granulation with pulverisation of solid particles, e.g. in a free-falling curtain
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
  • A23P10/00—Shaping or working of foodstuffs characterised by the products
  • A23P10/20—Agglomerating; Granulating; Tabletting
  • A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
  • A23P10/00—Shaping or working of foodstuffs characterised by the products
  • A23P10/40—Shaping or working of foodstuffs characterised by the products free-flowing powder or instant powder, i.e. powder which is reconstituted rapidly when liquid is added
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
  • A23P10/00—Shaping or working of foodstuffs characterised by the products
  • A23P10/40—Shaping or working of foodstuffs characterised by the products free-flowing powder or instant powder, i.e. powder which is reconstituted rapidly when liquid is added
  • A23P10/47—Shaping or working of foodstuffs characterised by the products free-flowing powder or instant powder, i.e. powder which is reconstituted rapidly when liquid is added using additives, e.g. emulsifiers, wetting agents or dust-binding agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
  • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/56—Materials from animals other than mammals
  • A61K35/60—Fish, e.g. seahorses; Fish eggs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/56—Materials from animals other than mammals
  • A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/02—Algae
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1617—Organic compounds, e.g. phospholipids, fats
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2013—Organic compounds, e.g. phospholipids, fats
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
  • A61K9/2806—Coating materials
  • A61K9/2833—Organic macromolecular compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
  • A61K9/2806—Coating materials
  • A61K9/2833—Organic macromolecular compounds
  • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
  • A61K9/2806—Coating materials
  • A61K9/2833—Organic macromolecular compounds
  • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
  • A61K9/2846—Poly(meth)acrylates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
  • A61K9/2806—Coating materials
  • A61K9/2833—Organic macromolecular compounds
  • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
  • A61K9/2806—Coating materials
  • A61K9/2833—Organic macromolecular compounds
  • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
  • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/02—Nutrients, e.g. vitamins, minerals
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
  • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
  • A23V2250/00—Food ingredients
  • A23V2250/18—Lipids
  • A23V2250/186—Fatty acids
  • A23V2250/1868—Docosahexaenoic acid
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
  • A23V2250/00—Food ingredients
  • A23V2250/18—Lipids
  • A23V2250/186—Fatty acids
  • A23V2250/187—Eicosapentaenoic acid

Definitions

• the present invention relates to an improved method for preparation of powder and tablets comprising omega-3 fatty acid derivatives and beta-cyclodextrin.
• Omega-3 comprising products are generally provided either in the form of oil encapsulated in soft capsules or in the form of free oil (cod liver oil products).
• omega-3 products with different and improved properties relative to omega-3 in the form of oil.
• These improved properties are one or more of the following: improved oxidative stability, reduced fish taste typically from gastrointestinal reflux, efficient uptake from the gastrointestinal system, improved technical possibilities to prepare stable combination products (products comprising omega-3 plus one or more active components like minerals, vitamins, drug substances or food additives) and finally omega-3 products that can be used in food products like drinks (e.g. juice) and semisolid/solid food products (e.g. yoghurt and bread).
• WO 2008/146016 A2 discloses a pharmaceutical or nutraceutical tablet for oral administration comprising at least two fatty acids or derivatives thereof at a high dosage level and cyclodextrin.
• the present invention relates to an improved method for preparation of powder and tablets comprising omega-3 fatty acid derivatives and beta-cyclodextrin.
• the claimed invention is strictly defined in the appended set of claims.
• compositions comprising a dry powder comprising beta-cyclodextrin in an amount of from 60% to 90% w/w of the powder and a lipid component in an amount of from about 10% to 40% w/w of the powder, wherein the lipid component is characterized as having a surfactant content of from about 10% to 35% w/w of the lipid component, as claimed.
• the lipid component comprises an omega-3 fatty acid or derivative thereof selected from the group consisting of omega-3 triglycerides.
• the omega-3 fatty acids or derivatives thereof have an EPA:DHA ratio of greater than 1:1.
• the omega-3 fatty acids or derivatives thereof have a DHA:EPA ratio of greater than 1:1.
• the omega-3 fatty acid or derivative thereof selected from the group consisting of omega-3 triglycerides comprises EPA and DHA fatty acids at a concentration of from 10% to 70% w/w of the fatty acids in the omega-3 triglycerides.
• the omega-3 fatty acid or derivative thereof selected from the group consisting of omega-3 triglycerides comprises EPA and DHA fatty acids at a concentration of from 30% to 60% w/w of the fatty acids in the omega-3 triglycerides.
• the surfactant is a diglyceride of fatty acids.
• the diglycerides of fatty acids comprise a mixture of diglyceride compounds wherein the fatty acid components of the diglycerides compounds are selected from saturated, monounsaturated and polyunsaturated fatty acids.
• the polyunsaturated fatty acids are omega-3 fatty acids.
• the omega-3 fatty acids are selected from EPA and DHA.
• the concentration of the surfactant in the lipid component is from 10% to 35% w/w of the lipid component.
• the powder composition is spray granulated. In some embodiments, the powder composition is spray granulated and has a particle size distribution of 50-650 microns. In some embodiments, the powder composition is spray granulated and has a particle size distribution of 200-500 microns.
• the present invention provides tableted lipid formulations comprising beta-cyclodextrin in a concentration of from 60% to 90% w/w of the tablet and a lipid component in a concentration of from 10% to 40% w/w of the tablet, wherein the lipid component is characterized as having a surfactant content of from 10% to 35% w/w of the lipid component, as claimed.
• the tablet has a crushing strength of greater than 5 kN. In some embodiments, the tablet has a crushing strength of greater than 7 kN. In some embodiments, the tablet has a crushing strength of from 5 to 10 kN.
• the present invention provides tableted lipid formulations comprising beta-cyclodextrin in a concentration of from 60% to 90% w/w of the tablet and a lipid component in a concentration of from 10% to 40% w/w of the tablet, wherein the lipid component is characterized as having a diglyceride content of from 10% to 35% w/w of the lipid component, wherein the tablet has a crushing strength of greater than 3 kN.
• the tablet has a crushing strength of greater than 5 kN. In some embodiments, the tablet has a crushing strength of greater than 7 kN. In some embodiments, the tablet has a crushing strength of from 5 to 10 kN.
• the omega-3 fatty acids or derivatives thereof have an EPA:DHA ratio of greater than 1:1. In some embodiments, the omega-3 fatty acids or derivatives thereof have a DHA:EPA ratio of greater than 1:1.
• the omega-3 triglycerides are a marine oil. In some embodiments, the marine oil is selected from the group consisting of fish oil, squid oil and algal oil. In some embodiments, the omega-3 fatty acid or derivative thereof selected from the group consisting of omega-3 triglycerides comprises EPA and DHA fatty acids at a concentration of from 10% to 70% w/w of the fatty acids in the omega-3 triglycerides.
• the omega-3 fatty acid or derivative thereof selected from the group consisting of omega-3 triglycerides comprises EPA and DHA fatty acids at a concentration of from 30% to 60% w/w of the fatty acids in the omega-3 triglycerides.
• the diglycerides comprise a mixture of diglyceride compounds wherein the fatty acid components of the diglycerides compounds are selected from saturated, monounsaturated and polyunsaturated fatty acids.
• the polyunsaturated fatty acids are omega-3 fatty acids.
• omega-3 fatty acids are selected from EPA and DHA.
• the tableted formulation is coated.
• the tableted formulation is coated with an agent selected from the group consisting of polyvinyl acetate, methyl acrylate-methacrylic acid copolymers, cellulose acetate phthalate (CAP), cellulose acetate succinate, hydroxypropyl methyl cellulose phthalate, hydroxypropyl methyl cellulose acetate succinate (hypromellose acetate succinate), polyvinyl acetate phthalate (PVAP), methyl methacrylate-methacrylic acid copolymers, cellulose acetate trimellitate, and sodium alginate.
• an agent selected from the group consisting of polyvinyl acetate, methyl acrylate-methacrylic acid copolymers, cellulose acetate phthalate (CAP), cellulose acetate succinate, hydroxypropyl methyl cellulose phthalate, hydroxypropyl methyl cellulose acetate succinate (hypromellose acetate succinate), polyvinyl acetate phthal
• the lipid component is combined with an additional nutraceutical agent that is not an omega-3 fatty acid or derivative thereof. In some embodiments, the lipid component is combined with an additional pharmaceutical agent that is not an omega-3 fatty acid or derivative thereof.
• the present invention provides processes for making a tabletable lipid powder comprising: combining an aqueous solution of beta-cyclodextrin with a lipid component in an amount of from 10% to 40% w/w of the beta-cyclodextrin the solution, wherein the lipid component comprises one or more surfactants at a concentration of from 10% to 35% w/w of the lipid component; mixing the aqueous solution of beta-cyclodextrin and the lipid component to provide a mixture; and removing water from the mixture to provide a dry powder, as claimed.
• the omega-3 fatty acids or derivatives thereof have an EPA:DHA ratio of greater than 1:1. In some embodiments, the omega-3 fatty acids or derivatives thereof have a DHA:EPA ratio of greater than 1:1.
• the omega-3 triglycerides are a marine oil. In some embodiments, the marine oil is selected from the group consisting of fish oil, squid oil and algal oil. In some embodiments, the omega-3 fatty acid or derivative thereof selected from the group consisting of omega-3 triglycerides comprises EPA and DHA fatty acids at a concentration of from 10% to 70% w/w of the fatty acids in the omega-3 triglycerides.
• the omega-3 fatty acid or derivative thereof selected from the group consisting of omega-3 triglycerides comprises EPA and DHA fatty acids at a concentration of from 20% to 45% w/w of the fatty acids in the omega-3 triglycerides.
• the surfactant is a diglyceride of fatty acids.
• the diglycerides of fatty acids comprise a mixture of diglyceride compounds wherein the fatty acid components of the diglycerides compounds are selected from saturated, monounsaturated and polyunsaturated fatty acids.
• the polyunsaturated fatty acids are omega-3 fatty acids.
• the omega-3 fatty acids are selected from EPA and DHA.
• the removing water from the mixture to provide a dry powder further comprises spray drying.
• the removal of water is performed as spray granulation and the powder has a particle size distribution of 50-650 microns.
• the removal of water is performed as spray granulation and the powder has a particle size distribution of 200-500 microns.
• the processes further comprise the step of forming a tablet from the dry powder.
• the tablet has a crushing strength of greater than 5 kN. In some embodiments, the tablet has a crushing strength of greater than 7 kN. In some embodiments, the tablet has a crushing strength of from 5 to 10 kN.
• the present invention relates to the method to use diglycerides, in the preparation process for powders comprising beta-cyclodextrin and omega-3 fatty acids and derivatives thereof and to the dry powders and tablets comprising diglycerides.
• the inventors unexpectedly observed that the addition of between 10% and 35% diglycerides to an omega-3 oil composition (% weight/weight (w/w) calculated as weight of diglycerides divided by the total weight of the diglycerides plus the weight of the oil) allowed for the production of a beta-cyclodextrin powder with superior tabletting properties as well as tablets with superior properties.
• the most preferred diglycerides for use in the present invention comprise a mixture of diglyceride compounds, where the fatty acid components in the mixture of diglyceride molecules can be saturated, monounsaturated and/or polyunsaturated, including omega-3 fatty acids like EPA and DHA.
• the diglyceride molecules typically comprise saturated, monounsaturated and/or polyunsaturated fatty acids of various number of carbon atoms and various number of double bonds.
• Some typical fatty acids include fatty acids belonging to one or more of the following groups of fatty acids: 14:0, 15:0, 16:0, 16: 1, 17:0, 18:0, 18: 1, 18:2, 18 :3, 18: 4, 20: 1, 20: 4, 20:5, 22: 1, 22:5 and 22:6.
• the first number represents the number of carbon atoms and the last number represents the number of double bonds.
• EPA belongs to the fatty acid group 20:5 with 20 carbon atoms and 5 double bonds
• DHA belongs to the fatty acid group 22:6 with 22 carbon atoms and 6 double bonds. Both EPA and DHA have cis (Z)-isomer double bonds.
• the diglycerides described according to the present invention might be naturally present in the oil or present in the oil as a result of the production process.
• the diglyceride might also be added to the oil before processing to a tablettable powder.
• the diglyceride content of the oil is adjusted to be in the range of from 10% to 35% of the weight of the oil on a w/w basis.
• the diglyceride can be in the form of 1,2-diacylglycerols and/or 1,3-diacylglycerols.
• Diglycerides of fatty acids are approved food additives as emulsifiers.
• the diglycerides preferably have an HLB of about 3.
• One of the most preferred aspects of the present invention is to use oil comprising a mixture of diglycerides where one or more of the single diglyceride molecular components are diglycerides with one or two EPA fatty acids or diglycerides with one or two DHA fatty acids.
• the other fatty acid might typically be an acid selected among the following groups of fatty acids: 14:0, 15:0, 16:0, 16: 1, 17:0, 18:0, 18: 1, 18:2, 18 :3, 18: 4, 20: 1, 20: 4, 20:5, 22: 1, 22:5 and 22:6.
• the other fatty acid might typically be an acid selected among the following groups of fatty acids: 14:0, 15:0, 16:0, 16: 1, 17:0, 18:0, 18: 1, 18:2, 18 :3, 18: 4, 20: 1, 20: 4, 20:5, 22: 1, 22:5 and 22:6.
• the present invention therefor relates to methods for preparation of powder and tablets comprising omega-3 fatty acid derivatives and beta-cyclodextrin and products prepared by the method.
• the method is characterized by including of one or more diglycerides during preparation of the aqueous slurry before preparation of the dry powder.
• the surfactant will generally be present in the powder and thereby the tablets.
• aspects of the present invention are therefore powders and tablets comprising omega-3 fatty acid derivatives, beta-cyclodextrin and one or more diglycerides.
• One aspect of the present invention relates to a method for preparation of dry powder comprising omega-3, beta-cyclodextrin using diglycerides.
• a preferred aspect of the method is a method for preparation of dry powder comprising omega-3, beta-cyclodextrin using diglycerides, where the dry powder is a tabletable powder.
• a more preferred aspect of this aspect of method is a method for preparation of dry powder comprising omega-3, beta-cyclodextrin using diglycerides, where the dry powder is a tabletable powder that can be tableted using standard tableting equipment producing more than 10,000 tablets per hour and the tablets can be prepared continuously for hours.
• beta-cyclodextrin, one or more omega-3 fatty acid and derivatives thereof, and diglycerides are combined in an aqueous mixture.
• the mixture is agitated, for example by stirring, for a period of from about 5 minutes to 300 minutes, preferably from about 30 to about 90 minutes, and most preferably for about 60 minutes.
• the water is then removed from the mixture, for example by evaporation under reduced pressure to yield a dry, tabletable powder.
• the water is preferably removed by spray drying or granulation.
• the powder has a particle size distribution of 50-650 microns, and most preferably from 200-500 microns, following spray drying or granulation.
• the oil component preferably comprises one or more omega-3 fatty acids or derivatives thereof.
• the one or more omega-3 fatty acids or derivatives thereof are selected from omega-3 triglycerides, alone or in combination.
• one or more of these omega 3 fatty acids and derivatives thereof are the main omega-3 components used to prepare the dry powder.
• one or more of these omega 3 fatty acids and derivatives thereof are the main oil components used to prepare the dry powder (e.g., the oil component used in the process comprises greater than about 60%, 70%, 80%, w/w of the specified omega-3 fatty acid or derivative thereof wherein w/w refers to the total weight of the specified omega-3 fatty acid or derivative thereof per the total weight of the oil component).
• one or more of these omega 3 fatty acids and derivatives thereof are from a marine source, such as fish, algae, or have been prepared from raw products from fish or algae.
• one or more of these omega 3 fatty acids and derivatives thereof are from plants or vegetables or have been prepared from raw products from plants and vegetables.
• the omega-3 fatty acids or derivatives are preferably selected from EPA and DHA and combinations thereof.
• the omega 3 fatty acids and derivatives thereof comprise more EPA than DHA.
• the omega 3 fatty acids and derivatives thereof comprise more DHA than EPA.
• the omega 3 fatty acids and derivatives thereof are enriched for EPA, e.g., more than 90% w/w of the total omega 3 fatty acids and derivatives thereof in the powder is EPA where the w/w% is the weight of EPA per total weight of fatty acids in the powder.
• the omega 3 fatty acids and derivatives thereof are enriched for DHA, e.g., more than 90% w/w of the total omega 3 fatty acids and derivatives thereof in the powder is DHA where the w/w% is the weight of DHA per total weight of fatty acids in the powder.
• the lipid component preferably comprises from about 30% to 60% w/w EPA and/or DHA.
• w/w refers to the total weight of surfactant (or combination thereof) to the total weight of the oil component.
• the surfactants are diglycerides and the most preferred surfactants are diglycerides where one or more of the acids are omega-3 fatty acids.
• the diglycerides comprise of a mixture of diglyceride compounds where the fatty acid components in the mixture of diglyceride molecules can be saturated, monounsaturated and polyunsaturated including omega-3 fatty acids like EPA and DHA.
• omega-3 oils comprising diglyceride for preparation of tablettable powder and tablets that other surfactants or surfactant mixtures with similar HLB-values will be as helpful as diglycerides.
• additional active ingredients may be included in the lipid component along with omega-3 fatty acids or derivatives thereof.
• suitable additional active ingredients include, but are not limited to other active fatty acids such as omega-6 fatty acids, conjugated fatty acids such as conjugated linoleic acid fatty acid, and lipophilic drugs such as as Class II and Class IV drugs as classified under the Biopharmaceutics Classification System.
• a variety a nutraceutical and pharmaceutical agents may be included in the lipid component.
• the nutraceutical and pharmaceutical agents are lipophilic.
• the active ingredient is a pharmaceutical ingredient selected from the groups consisting of antineoplastic, antifungal, antiviral, anticonvulsant, antiepileptic, immunosuppressant, and erectile dysfunction drugs.
• the BCS is a guide for predicting the intestinal drug absorption provided by the U.S. Food and Drug Administration. This system restricts the prediction using the parameters solubility and intestinal permeability.
• Class I high permeability, high solubility (compounds are well absorbed at all GI PH and their absorption rate is usually higher than excretion); Class II- high permeability, low solubility (bioavailability of those products is limited by their solubility and rate of dissolution Class III - low permeability, high solubility (absorption is limited by the permeation rate but the drug is solvated very fast; if the formulation does not change the permeability or gastro-intestinal duration time, then class I criteria can be applied); Class IV - low permeability, low solubility (compounds have a poor bioavailability; usually they are not well absorbed over the intestinal mucosa and a high variability is expected).
• Solubility class boundaries are based on the highest dose strength of an immediate release product. A drug is considered highly soluble when the highest dose strength is soluble in 250ml or less of aqueous media over the ph range of I to 7.5. The volume estimate of 250ml is derived from typical bioequivalence study protocols that prescribe administration of a drug product to fasting human volunteers with a glass of water. Permeability class boundaries are based indirectly on the extent of absorption of a drug substance in humans and directly on the measurement of rates of mass transfer across human intestinal membrane.
• non-human systems capable of prediction the drug absorption systems capable of predicting the drug absorption in humans can be used (such as in-vitro culture methods).
• a drug substance is considered highly permeable when the extent of absorption in humans is determined to be 90% or more of the administered dose based on a mass-balance determination or in comparison to and intravenous dose.
• dissolution class boundaries an immediate release products is considered rapidly dissolving when no less than 85% of the labeled amount of the drug substance dissolve within 15 minutes using USP Dissolution Apparatus 1 at 100 RPM or Apparatus 2 at 50 RPM in a volume of900ml or less in following media,) 0.1 N HCI or simulated gastric fluid or pH 4.5 buffer and pH 6.8 buffer or simulated intestinal fluid.
• the additional active ingredient is a drug including, but not limited to the following drugs: tripranavir, cefditoren pivoxil, tadalafil, mycophenolic acid, posaconazole, lapatinib, bromocriptine, ticagrelor, sorafetinib, itraconazole, erlotinib, sirolimus, alvimopan, naltrexone, vardenafil, rosuvastatin, maraviroc, ritonavir, efavirez, celecoxib, atovaquone, raloxifene, finasteride, everolimus, and dodrenarone.
• drugs including, but not limited to the following drugs: tripranavir, cefditoren pivoxil, tadalafil, mycophenolic acid, posaconazole, lapatinib, bromocriptine, ticagrelor, sorafetinib, itraconazole
• the additional active ingredient is selected from the groups consisting of antineoplastic, antifungal, antiviral, anticonvulsant, antiepileptic, antidepressant, immunosuppressant, anti-inflammatory and erectile dysfunction drugs.
• exemplary antineoplastic drugs suitable for use as an additional active ingredient include, but are not limited to: I) alkaloids, including microtubule inhibitors (e.g., vincristine, vinblastine, and vindesine, etc.), microtubule stabilizers (e.g., paclitaxel (TAXOL), and docetaxel, etc.), and chromatin function inhibitors, including topoisomerase inhibitors, such as epipodophyllotoxins (e.g., etoposide (VP-16), and teniposide (VM-26), etc.), and agents that target topoisomerase I (e.g., camptothecin and isirinotecan (CPTII), etc.); 2) covalent DNA-binding agents (alkylating agents), including nitrogen mustards (e.g., mechlorethamine, chlorambucil, cyclophosphamide, ifosphamide, and busulfan (MYLERAN), etc.),
• exemplary antifungal drugs suitable for use as an additional active ingredient include, but are not limited to nystatin, amphotericin B, griseofulvin, miconazole, ketoconazole, terbinafine, itraconazole, fluconazole, posaconazole, and voriconazole.
• exemplary antiviral drugs suitable for use in dosage forms of the present invention include, but are not limited to abacavir, aciclovir, acyclovir, adefovir, amantadine, amprenavir, ampligen, arbidol, atazanavir, atripla, boceprevir, cidofovir, combivir, darunavir, delavirdine, didanosine, docosanol, edoxudine, efavirenz, emtricitabine, enfuvirtide, entecavir, famciclovir, fomivirsen, fosamprenavir, foscamet, fosfonet, ganciclovir, ibacitabine, imunovir, idoxuridine, imiquimod, indinavir, inosine, lamivudine, lopinavir, loviride, maraviroc, moroxydine, methisazone
• exemplary anticonvulsant drugs suitable for use as an additional active ingredient include, but are not limited to pregabalin, gabapentin, carbamazepine, and oxcarbazepine.
• exemplary antiepileptic and anticonvulsant drugs suitable for use as an additional active ingredient include, but are not limited to pregabalin, gabapentin, carbamazepine, and oxcarbazepine and alprazolam, bretazenil, bromazepam, brotizolam, chlordiazepoxide, cinolazepam, clonazepam, clorazepate, clotiazepam, cloxazolam, delorazepam, diazepam, estazolam, etizolam, flunitrazepam, flurazapam, flutoprazepam, halazepam, ketazolam, loprazolam, lorazepam, lormetazepam, medazepam, midazolam, nemetazepam, nitrazepam, nordazepam, oxazepam,
• exemplary antidepressant drugs suitable for use as an additional active ingredient include, but are not limited to tricyclic compounds such as bupropion, nortriptyline, desipramine, amitriptyline, amitriptylinoxide, butriptyline, clomipramine, demexiptiline, dibenzepin, dimetacrine, dosulepin/dothiepin, doxepin, imipramine, amineptine, iprindole, opipramol, tianeptine, trimipramine, imipraminoxide, lofepramine, melitracin, metapramine, nitroxazepine, noxiptiline, pipofezine, propizepine, protriptyine, and quinupramine; SNRis such as duloxetine, venlafaxine, desvenlafaxine, milnacipran, levomilnacipran, sibutramine, bicifadine
• exemplary immunosuppressant drugs suitable for use as an additional active ingredient include, but are not limited to azathioprine, mycophenolic acid, leflunomide, teriflunomide, methotrexate, tacrolimus, cyclosporin, pimecrolimus, abetimus, gusperimus, thalidomide, lenalidomide, anakinra, sirolimus, everolimus, ridaforolimus, tesirolimus, umirolimus, and zotarolimus.
• exemplary erectile dysfunction drugs suitable for use as an additional active ingredient include, but are not limited to Tadalafil, Vardenafil, Sildenafil, Alprostadil, Papaverine, and Phentolamine.
• the additional active ingredient is a non-steroidal anti-inflammatory drugs (NSAIDS).
• NSAIDS can, for example, be selected from the following: choline salicylate (Arthropan) celecoxib (Celebrex); diclofenac potassium (Cataflam); diclofenac sodium (Voltaren, Voltaren XR); diclofenac sodium with misoprostol (Arthrotec); diflunisal (Dolobid); etodolac (Lodine, Lodine XL); fenoprofen calcium (Nalfon); flurbiprofen (Ansaid); ibuprofen (Advil, Motrin, Motrin IB, Nuprin); indomethacin (Indocin, Indocin SR); ketoprofen (Actron, Orudis, Orudis KT, Oruvail); magnesium salicylate (Arthritab, Bayer Select, Doan's Pills, Magan, MoAridine
• the dry powders of the present invention are tabletable powders.
• the dry powders of the present invention can be tableted using standard tableting equipment producing more than 10,000 tablets per hour and the tablets can be prepared continuously for hours.
• the present powder is prepared from the aqueous mixture by removing the water.
• the process for preparation of dry powder include various state of the art methods within pharmaceutical production like drying at increased temperature, vacuum drying, freeze drying, spray drying and spray granulation. Spray drying/spray granulation methods are the most preferred methods for preparation of tablettable powder.
• the powders of the present invention comprise an oil component and beta-cyclodextrin in a defined ratio which may preferably be expressed as a weight/weight (w/w) percentage of the oil component in the powder.
• the powders of the present invention therefore comprise from 10% to 40%, 20% to 40%, 30% to 40%, 10% to 35%, 20% to 35%, 25% to 35%, 30% to 35%, at least 10%, at least 20%, at 30% or at least 35% w/w of an oil component, wherein w/w refers to the total weight of the oil component to the total weight of the powder.
• one or more of these omega 3 fatty acids and derivatives thereof are the main omega-3 components in the dry powder. In some embodiments, one or more of these omega 3 fatty acids and derivatives thereof are the main oil components in the dry powder (e.g., the oil component in the powder comprises greater than about 70%, 80%, w/w of the specified omega-3 fatty acid or derivative thereof wherein w/w refers to the total weight of the specified omega-3 fatty acid or derivative thereof per the total weight of the oil component). In some embodiments, one or more of these omega 3 fatty acids and derivatives thereof are from a marine source, such as fish, algae, or have been prepared from raw products from fish or algae.
• one or more of these omega 3 fatty acids and derivatives thereof are from plants or vegetables or have been prepared from raw products from plants and vegetables.
• the lipid component preferably comprises from about 30% to 60% w/w EPA and/or DHA.
• the lipid component, and thus the powders may comprise an additional active ingredient as described in detail above.
• the omega-3 fatty acids or derivatives are preferably selected from EPA and DHA and combinations thereof.
• the omega 3 fatty acids and derivatives thereof comprise more EPA than DHA (i.e., the ratio of EPA: DHA is greater than 1:1).
• the omega 3 fatty acids and derivatives thereof comprise more DHA than EPA (i.e., the ratio of DHA: EPA is greater than 1:1).
• the omega 3 fatty acids and derivatives thereof are enriched for EPA, e.g., more than 90% w/w of the total omega 3 fatty acids and derivatives thereof in the powder is EPA where the w/w is the weight of EPA per total weight of fatty acids in the powder.
• the omega 3 fatty acids and derivatives thereof are enriched for DHA, e.g., more than 90% w/w of the total omega 3 fatty acids and derivatives thereof in the powder is DHA where the w/w% is the weight of DHA per total weight of fatty acids in the powder.
• the powders may be further characterized according to their total omega-3 content.
• the dry powders of the present invention comprise more than 10% w/w, more than 15% w/w, more than 20% w/w, more than 25% w/w or more than 30% w/w of omega-3 triglycerides.
• the dry powders of the present invention are tabletable powders.
• the dry powders of the present invention can be tableted using standard tableting equipment producing more than 10,000 tablets per hour and the tablets can be prepared continuously for hours.
• the tablets have a crushing strength of greater than 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 kN, or from about 3 to 50, 3 to 40, 3 to 30, 3 to 20, 5 to 50, 5 to 40, 5 to 30, 5 to 20, 5 to 10, 7 to 50, 7 to 40, 7 to 30, 7 to 20, 10 to 50, 10 to 40, 10 to 30, or 10 to 20 kN.
• the tablets of the present invention comprise an oil component and beta-cyclodextrin in a defined ratio which may preferably be expressed as a weight/weight (w/w) percentage of the oil component in the powder.
• the tablets of the present invention therefore comprise from 10% to 40%, 20% to 40%, 30% to 40%, 10% to 35%, 20% to 35%, 25% to 35%, 30% to 35%, at least 10%, at least 20%, at 30% or at least 35% w/w of an oil component, wherein w/w refers to the total weight of the oil component to the total weight of the tablet.
• one or more of these omega 3 fatty acids and derivatives thereof are the main omega-3 components used to prepare the dry powder. In some embodiments, one or more of these omega 3 fatty acids and derivatives thereof are the main omega-3 components in the dry powder. In some embodiments, one or more of these omega 3 fatty acids and derivatives thereof are the main oil components in the dry powder (e.g., the oil component in the powder comprises greater than about 70%, 80%, w/w of the specified omega-3 fatty acid or derivative thereof wherein w/w refers to the total weight of the specified omega-3 fatty acid or derivative thereof per the total weight of the oil component).
• one or more of these omega 3 fatty acids and derivatives thereof are from a marine source, such as fish, algae, or have been prepared from raw products from fish or algae. In some embodiments, one or more of these omega 3 fatty acids and derivatives thereof are from plants or vegetables or have been prepared from raw products from plants and vegetables.
• the lipid component used to prepare the powder and thus the tablets may comprise an additional active ingredient as described in detail above.
• the omega-3 fatty acids or derivatives are preferably selected from EPA and DHA and combinations thereof.
• the omega 3 fatty acids and derivatives thereof comprise more EPA than DHA (i.e., the ratio of EPA: DHA is greater than 1:1).
• the omega 3 fatty acids and derivatives thereof comprise more DHA than EPA (i.e., the ratio of DHA: EPA is greater than 1:1).
• the omega 3 fatty acids and derivatives thereof are enriched for EPA, e.g., more than 90% w/w of the total omega 3 fatty acids and derivatives thereof in the powder is EPA where the w/w is the weight of EPA per total weight of fatty acids in the powder.
• the omega 3 fatty acids and derivatives thereof are enriched for DHA, e.g., more than 90% w/w of the total omega 3 fatty acids and derivatives thereof in the powder is DHA where the w/w% is the weight of DHA per total weight of fatty acids in the powder.
• the lipid component preferably comprises from about 30% to 60% w/w EPA and/or DHA.
• the tablets may be further characterized according to their total omega-3 content.
• the tablets of the present invention comprise more than 10% w/w, more than 15% w/w, more than 20% w/w, more than 25% w/w or more than 30% w/w of omega-3 triglycerides where w/w refers to the total weight of the omega-3 triglycerides per the total weight of the tablet.
• the tablets of the present invention comprise a surfactant in a defined ratio to the amount of the oil component in the tablet, from 10% to 20% w/w, 10% to 30% w/w, 15% to 30% w/w, 18% to 30% w/w, 20% to 30% w/w, or 10% to 35% w/w surfactant or combination of surfactants, wherein w/w refers to the total weight of surfactant (or combination thereof) to the total weight of the oil component including the surfactant.
• the surfactants in tablets are diglycerides and the most preferred surfactants are diglycerides where one or more of the acids are omega-3 fatty acids.
• the typically most preferred diglycerides comprise of a mixture of diglyceride compounds where the fatty acid components in the mixture of diglyceride molecules can be saturated, monounsaturated and/or polyunsaturated, including omega-3 fatty acids like EPA and DHA.
• the tablets are coated.
• Suitable coatings include, but are not limited to, polyvinyl acetate, methyl acrylate-methacrylic acid copolymers, cellulose acetate phthalate (CAP), cellulose acetate succinate, hydroxypropyl methyl cellulose phthalate, hydroxypropyl methyl cellulose acetate succinate (hypromellose acetate succinate), polyvinyl acetate phthalate (PVAP), methyl methacrylate-methacrylic acid copolymers, cellulose acetate trimellitate, and sodium alginate.
• CAP cellulose acetate phthalate
• PVAP polyvinyl acetate phthalate
• Example 1 Preparation of 30:70 triglyceride:beta-cyclodextrin complexes with diglycerides.
• Beta-cyclodextrin 1000g was suspended in water at room temperature. A mixture of EPA and DHA (60% w/w) and various fatty acids as triglycerides, diglycerides and monoglycerides (430 g) was added. The mixture was stirred for 1 hour. The water was evaporated. The product was off-white, tabletable powder.
• the product was prepared as in example 1 with oil with glyceride composition (triglycerides/diglycerides/monoglycerides) as 91/7/1 area %.
• the product was a slurry with obvious oil layers, it was not possible to prepare dry powders from this mixture.
• Example 3 Preparation of 30:70 triglyceride:beta-cyclodextrin complexes prepared with 19 area % diglycerides.
• the product was prepared as in example 1 with oil with glyceride composition (triglycerides/diglycerides/monoglycerides) as 80/19/1 area %.
• the product was dry, off-white to yellow powder.
• the powder was tabletable.
• Example 4 Preparation of 30:70 triglyceride:beta-cyclodextrin complexes prepared with 24 area % diglycerides.
• the product was prepared as in example 1 with oil with glyceride composition (triglycerides/diglycerides/monoglycerides) as 74/25/1 area %.
• the product was dry, off-white powder.
• the powder was directly tabletable.
• Example 5 Preparation of 30:70 triglyceride:beta-cyclodextrin complexes prepared with 32 area % diglycerides.
• the product was prepared as in example 1 with oil with glyceride composition (triglycerides/diglycerides/monoglycerides) as 67/32/1 area %.
• the product was dry, off-white powder.
• the powder was directly tabletable.
• Example 6 Preparation of 30:70 triglyceride:beta-cyclodextrin complexes prepared with 34 area % diglycerides.
• the product was prepared as in example 1 with oil with glyceride composition (triglycerides/diglycerides/monoglycerides) as 65/34/1 area %.
• the product was dry, off-white powder.
• the powder was directly tabletable.
• Example 7 Tablets prepared from 30:70 triglyceride:beta-cyclodextrin complexes prepared with 27 area % diglycerides.
• Tablets comprising 96% (w/w) triglyceride:beta-cyclodextrin complexes prepared from oil with glyceride composition (triglycerides/diglycerides/monoglycerides) as 74/25/1 area % was prepared in a conventional tableting machine.
• the tablets achieved a crushing strength of 9.1 kN.
• the powder was prepared as in example 1, the method for water evaporation was spray granulation.
• the powder comprised of rounded particles with particle size distribution between 50-650 microns.
• the powder was directly tablettable.
• Example 9 Preparation of 30:70 triglyceride:beta-cyclodextrin complexes with different content of diglyceride (DG) optionally added a surfactant.
• DG diglyceride
• the powder products were prepared as in example 1, spray granulated when complexes were achieved and tableted.
• EE60 comprise 60 % omega-3
• EE5325 comprise 33% EPA and 23%DHA
• EE4020 comprise 40% EPA and 20% DHA.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Polymers & Plastics (AREA)
• Food Science & Technology (AREA)
• Nutrition Science (AREA)
• Mycology (AREA)
• Biophysics (AREA)
• Molecular Biology (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Obesity (AREA)
• Hematology (AREA)
• Diabetes (AREA)
• Marine Sciences & Fisheries (AREA)
• Biotechnology (AREA)
• Natural Medicines & Medicinal Plants (AREA)
• Botany (AREA)
• Alternative & Traditional Medicine (AREA)
• Medical Informatics (AREA)
• Microbiology (AREA)
• Zoology (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicinal Preparation (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Medicines Containing Plant Substances (AREA)

Applications Claiming Priority (2)

Publications (2)

Family

ID=58994957

Family Applications (1)

Country Status (11)

Families Citing this family (5)

Family Cites Families (18)

• 2017
  • 2017-03-15 CA CA3017825A patent/CA3017825C/en active Active
  • 2017-03-15 EP EP17727684.7A patent/EP3429377B1/en active Active
  • 2017-03-15 CN CN201780023590.1A patent/CN109068707B/zh active Active
  • 2017-03-15 WO PCT/IB2017/000548 patent/WO2017158439A1/en active Application Filing
  • 2017-03-15 AU AU2017232554A patent/AU2017232554B2/en not_active Ceased
  • 2017-03-15 KR KR1020187029829A patent/KR102263900B1/ko active Active
  • 2017-03-15 ES ES17727684T patent/ES2836729T3/es active Active
  • 2017-03-15 JP JP2019500035A patent/JP6738477B2/ja active Active
  • 2017-03-15 US US16/085,178 patent/US20190364946A1/en not_active Abandoned
  • 2017-03-15 BR BR112018068855A patent/BR112018068855A2/pt not_active IP Right Cessation
• 2018
  • 2018-09-14 CL CL2018002656A patent/CL2018002656A1/es unknown

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events